Nicole Fett, MD
Dermatology · Portland, ORNPI 1184682437
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $3,073 of the $3,496 with a category attached, or 87.9%. Sanofi-aventis U.S. LLC accounts for 87.9% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2022 at $3,084 and has fallen 91.8% since, to $254 in 2025.
Across 6 payments — averaging $582.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Sanofi-aventis U.S. LLC$3K
- Astrazeneca UK Limited$254
- Pfizer$169
Across 4 payments — averaging $13,719 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$42K
- Pfizer$13K
What the payments were for
- Speaking & faculty fees$3,07388%
- Travel & lodging$1254%
- Food & beverage$2818%
- Education$170%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Sanofi-aventis U.S. LLC | 1 | $3,073 |
| Astrazeneca UK Limited | 2 | $254 |
| Pfizer | 3 | $169 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,496 in reported general payments places this provider in the 65th percentile of 175 dermatology providers in Oregon.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| StelaraUstekinumab | 11 | $309,145 |
| Dupixent PenDupilumab | 23 | $132,923 |
| Dupixent SyringeDupilumab | 17 | $110,017 |
| OpzeluraRuxolitinib Phosphate | 14 | $27,905 |
| Tacrolimus | 44 | $7,181 |
| Acitretin | 11 | $4,160 |
| Clobetasol Propionate | 90 | $3,095 |
| Fluorouracil | 33 | $2,406 |
| Dapsone | 17 | $1,865 |
| Doxycycline Hyclate | 32 | $1,377 |
| Hydroxychloroquine Sulfate | 54 | $1,365 |
| Triamcinolone Acetonide | 110 | $1,352 |
| Mycophenolate Mofetil | 13 | $1,221 |
| Doxycycline Monohydrate | 22 | $1,065 |
| Ketoconazole | 57 | $1,029 |
Paid to pharmacies, not to this prescriber.
Other dermatology in Portland
- Andrew BlauveltPortland$1.8M
- Benjamin EhstPortland$1.5M
- Jason HawkesPortland$1.5M
- Eric SimpsonPortland$1.4M
- Alex Ortega LoayzaPortland$122K
- Omar QutubPortland$107K
- Paul HaunPortland$85K
- Kathryn SchwarzenbergerPortland$34K
- Jon HanifinPortland$25K
- Phoebe RichPortland$17K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.